Speaker Profile
M.D., Endowed Professor, OHSU; co-Founder Pathomiq, PATHOMIQ
Biography
Dr. Shivaani Kummar is Associate CEO and interim Director, Knight Cancer Institute, Endowed Professor and Division Chief of Hematology and Medical Oncology, and co-Director of the Center of Experimental Therapeutics, Oregon Health Science University, Portland, Oregon, USA. Prior to joining OHSU in 2020, she was on faculty at Yale University Cancer Center, served as Head of Early Clinical Trials Development Office of the Director, Division of Cancer Treatment and Diagnosis, NCI, and was Professor and Director of the Phase 1 Clinical Research Program and Translational Oncology Program at Stanford University, California. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel agents for further clinical investigation. She has authored over 180 peer reviewed publications, 9 book chapters, and co-edited a book. She is the co-founder of Pathomiq, a company that has developed an AI platform to predict response to treatment.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Alex Morgan, Khosla Ventures and Gad Getz, Broad Institute
PMWC Award Ceremony
• Steve Wozniak, Apple
• Greg Brockman, OpenAI
Fireside Chat
• Vinod Khosla, Khosla Ventures
• Greg Brockman, OpenAI
Target Discovery: Beyond Genomics – Revealing Hidden Layers of Biology with AI
• Keynote: Stephen Quake, CZ Biohub
• Chair: Cindy Lawley, Olink
• Aritro Nath, City of Hope
• Massa Shoura, Phinomics
• Omar Serang, DNAnexus
Accelerating Immunotherapy Discovery Through Multimodal AI
• Ron Alfa, Noetik
A Data-Integrated Approach to Target and Biomarker Discovery
• Liat Dassa, Cytoreason
Harmonizing Data to Accelerate Drug Discovery
• Vitalay Fomin, Numenos
Closing the Loop: Coupling AI with In Vivo Validation
• Gabriel Musso, Biosymetrics
Interpretable AI for Biomarker Discovery: Accelerating Drug Development
• Sanoj Punnen, University of Miami
• Shivanni Kummar, OHSU
• Mark Burkard, UI
Can AI Really Create the Next Blockbuster Drug?
• Chair: Amar Das, Guardant Health
• Ari Caroline, Weave Bio
• Dina Katabi, Emerald/MIT
• Andrei Georgescu, Vivodyne
• James Zou, Stanford
Gemini Digital Twins Accelerate Precision Medicine
• Collin Hill, Aitia
Scaling Rare Disease Discovery with AI
• Lisa Gurry, GeneDx
Enabling Targeted Precision Drug & Gene Delivery with Predictive AI
• Andre Watson, Ligandal
Is AI the New Drug or the New Therapeutic Modality
• Chair: Alex Morgan, Khosla Ventures
• Michael J. Kahana, Nia Therapeutics
• Marc Tessier-Lavigne, Xaira
